Debra Stephanie Barker
Directeur Technique/Scientifique/R&D chez DESTINY PHARMA PLC
Fortune : 34 010 $ au 30/06/2024
Profil
Debra Stephanie Barker is currently serving as a Non-Executive Director at CureVac SE.
She is also a Senior Independent Non-Executive Director at Destiny Pharma Plc, a Non-Executive Director at BerGenBio ASA, a Senior Independent Non-Executive Director at Arix Bioscience Plc, a Director at Hutman Diagnostics AG, a Senior Independent Director at Arix Bioscience, and a Member-Supervisory Board at CureVac NV.
In her former positions, Dr. Barker worked as the Head of Development, Anti-Infectives & Immunology at Novartis AG and as the Chief Medical & Development Officer at Spexis Ltd.
from 2017 to 2018.
Dr. Barker completed her graduate degree at King's College London and holds a doctorate degree from Queens' College Cambridge.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CUREVAC N.V.
0,00% | 15/03/2024 | 7 125 ( 0,00% ) | 24 225 $ | 30/06/2024 |
DESTINY PHARMA PLC
0,09% | 25/05/2023 | 88 461 ( 0,09% ) | 9 785 $ | 30/06/2024 |
Postes actifs de Debra Stephanie Barker
| Sociétés | Poste | Début |
|---|---|---|
| BERGENBIO ASA | Directeur/Membre du Conseil | 13/03/2019 |
| DESTINY PHARMA PLC | Directeur Technique/Scientifique/R&D | 01/10/2023 |
| CUREVAC N.V. | Directeur/Membre du Conseil | 22/06/2022 |
| ARIX BIOSCIENCE PLC | Directeur/Membre du Conseil | 10/08/2022 |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Directeur/Membre du Conseil | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Directeur/Membre du Conseil | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Directeur/Membre du Conseil | 01/08/2022 |
Anciens postes connus de Debra Stephanie Barker
| Sociétés | Poste | Fin |
|---|---|---|
| SPEXIS AG | Directeur Technique/Scientifique/R&D | 31/12/2018 |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formation de Debra Stephanie Barker
| King's College London | Graduate Degree |
| Queens' College Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| NOVARTIS AG | Health Technology |
| SPEXIS AG | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| BERGENBIO ASA | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| CUREVAC N.V. | Health Technology |
| Entreprise privées | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
